Table 5.
CircRNA | Research Model | Targeted Pathways | Mediator | Effects on PKM2 Expression | Biological/Physiological Effects | Significance |
---|---|---|---|---|---|---|
Circ-MAT2B | Hepatocellular Carcinoma (HCC) | Glycolysis Cell proliferation Invasion |
miR-338-3p | Overexpression of Circ-MAT2B increased protein and mRNA PKM2 levels | Circ-MAT2B overexpression increases HCC glucose utilization, tumor growth, and metastasis in vivo Circ-MAT2B overexpression promoted glycolysis, cell proliferation, migration, and invasion in vitro under hypoxia [282] |
Circ-MAT2B is associated with and predicts poor prognosis of HCC Targeting circ-MAT2B may alleviate HCC burden |
Circ-FOXM1 | Melanoma | Proliferation Glycolysis Invasion Apoptosis |
miR-143-3p | Silencing CircFOXM1 decreased PKM2 protein levels |
Increased proliferation, glycolysis, motility, and decreased apoptosis [374] | Circ-FOXM1 may promote melanoma progression through the miR-143-3p/FLOT2 axis |
Circ-NRIP1 | Gastric Cancer | Proliferation Migration Glycolysis Apoptosis |
miR-186-5p | Silencing of circ-NRIP1 decreased PKM2 protein levels | Circ-NRIP1 KD decreased proliferation, migration, and glycolysis but induced apoptosis [375] | Circ-NRIP1 promoted carcinogenesis and may have potential in prognostic and clinical application |
Circ-FOXP1 | Gallbladder Cancer |
Proliferation Migration Invasion Apoptosis Glycolysis |
miR-370 | Silencing of circFOXP1 resulted in a partial reduction in PKM2 protein level | Promotes proliferation, invasion, migration and decreases apoptosis [376] | Circ-FOXP1 may sponge miR-370 and promote PKLR expression, enhancing tumor progression |
Circ-RNA hsa_circ_0005963 (ciRS-122) | CRC | Glycolysis Apoptosis |
miR-122 | Exosome delivery of CiRS-122 upregulated PKM2 levels |
CiRS-122 delivery may promote drug resistance and glycolysis, and exosome-delivered siRNA appeared to reverse the resistance to treatment [377] | CiRS-122 silencing may promote enhanced therapeutic effectiveness against oxaliplatin-resistant CRC |